Neoprobe Newswire

Neoprobe Newswire

Comprehensive Real-Time News Feed for Neoprobe.

Results 1 - 20 of 99 in Neoprobe

  1. Navidea Biopharmaceuticals to Present at Sidoti Emerging Growth ConferenceRead the original story

    Tuesday Aug 25 | Freshnews

    Navidea Biopharmaceuticals, Inc. , announces that Rick Gonzalez, President and Chief Executive Officer, will present a corporate overview on Wednesday, September 2, 2015 at 1:30 PM EDT at the Sidoti Emerging Growth Conference , taking place at the Marriott Marquis in Times Square, New York City, NY. A live webcast of Mr. Gonzalez's presentation can be accessed at the following URL: .

    Comment?

  2. Navidea To Register Shares For Dual Listing On Tel-Aviv Stock ExchangeRead the original story

    Sunday Aug 23 | BioSpace

    Navidea Biopharmaceuticals Inc., , a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents, today announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange . Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.

    Comment?

  3. Navidea Biopharmaceuticals to Register Shares for Dual Listing on Tel-Aviv Stock ExchangeRead the original story

    Monday Aug 24 | Freshnews

    Navidea Biopharmaceuticals Inc., , a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents, today announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange . Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.

    Comment?

  4. Navidea Reports Publication Of Lymphoseek Comparative Results In...Read the original story

    Wednesday Aug 19 | BioSpace

    Navidea Biopharmaceuticals , announces publication of the results from an investigator-initiated, comparative study of LymphoseekA injection versus filtered Tc-99m Sulfur Colloid measuring injection site pain in patients with breast cancer undergoing lymphoscintigraphy. The paper titled, " Comparison of Post-injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy ," was published online in the Annals of Surgical Oncology [DOI - 10.1245/s10434-015-4802-y] and indicated, with patient-reported data, a statistically significant reduction in the level of post-injection associated pain using Lymphoseek compared with use of an fTcSC tracer.

    Comment?

  5. Navidea Biopharmaceuticals Sees Significant Increase in Short InterestRead the original story w/Photo

    Tuesday Aug 11 | AmericanBankingNews.com

    Shares of Navidea Biopharmaceuticals were the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 30,199,779 shares, an increase of 0.8% from the July 15th total of 29,963,980 shares, MarketBeat.com reports.

    Comment?

  6. Navidea Biopharmaceuticals Upgraded at ZacksRead the original story w/Photo

    Tuesday Aug 11 | AmericanBankingNews.com

    ... development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio. " Shares of Navidea Biopharmaceuticals ( NASDAQ:NAVB ) traded down 2.33% during ...

    Comment?

  7. BIND Therapeutics' (BIND) CEO Andrew Hirsch on Q2 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Thursday Aug 6 | Seeking Alpha

    Welcome to BIND Therapeutics Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

    Comment?

  8. Report Published: 'Navidea Biopharmaceuticals, Inc. (NAVB)'Read the original story

    Saturday Aug 1 | PR-inside.com

    Navidea Biopharmaceuticals, Inc. , formerly Neoprobe Corporation, is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. The company by utilizing its Manocept platform develops multiple precision-targeted products to identify pathways of undetected disease to provide better diagnostic accuracy, clinical decision-making and effective treatment.

    Comment?

  9. Navidea Biopharmaceuticals' (NAVB) CEO Rick Gonzalezon Q2 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Jul 30, 2015 | Seeking Alpha

    Good day ladies and gentlemen and welcome to the Navidea Biopharmaceuticals Second Quarter 2015 Financial Results. At this time all participants are in a listen-only mode.

    Comment?

  10. Navidea Reports Second Quarter 2015 Financial Results; Reiterates 2015 LymphoseekA Revenue GuidanceRead the original story

    Jul 30, 2015 | Freshnews

    Navidea Biopharmaceuticals, Inc. , today announced financial results for the second quarter of 2015. Navidea reported total revenue for the second quarter of 2015 of $2.9 million, including Lymphoseek injection sales revenue of $2.0 million.

    Comment?

  11. Navidea Biopharmaceuticals Is Vastly UndervaluedRead the original story w/Photo

    Jul 28, 2015 | Seeking Alpha

    Overview In this article, we focus only on Navidea's cancer diagnostic product Lymphoseek as a driver for future valuations. Lymphoseek is a cancer diagnostics tool, commercialized in the USA , and realizing 20% Q/Q sustained sales gains at a greater than 90% reorder rate, with an expanding market.

    Comment?

  12. BIND Therapeutics To Report Second Quarter 2015 Financial Results On August 6, 2015Read the original story

    Jul 27, 2015 | BioSpace

    BIND Therapeutics, Inc. , a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced it will host a conference call and live audio webcast on August 6, 2015, at 8:30 a.m. ET to report second quarter 2015 financial results. To access the conference call, please dial 312-5844 or 237-1152 at least five minutes prior to the start time and refer to conference ID 96619516.

    Comment?

  13. Navidea To Announce Second Quarter 2015 Financial Results On July 30, 2015Read the original story

    Jul 22, 2015 | BioSpace

    Navidea Biopharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter 2015, on Thursday, July 30, 2015 prior to a conference call with the investment community, scheduled at 8:30 a.m. EDT. Investors and the public are invited to access the live audio webcast through the link below.

    Comment?

  14. Navidea Release: Verification Of Lymphoseek Mechanism Of Action Published In /iRead the original story

    Jul 22, 2015 | BioSpace

    Navidea Biopharmaceuticals, Inc. , today announced the peer-reviewed publication of data verifying the LymphoseekA injection CD206-binding mechanism of action in the Journal of Immunology . Strong evidence-based studies demonstrate macrophages are the major target cell and identify CD206, the mannose receptor, as the tilmanocept-binding receptor.

    Comment?

  15. Verification of Lymphoseek Mechanism of Action Published in Journal of ImmunologyRead the original story

    Jul 23, 2015 | Business Wire

    Strong evidence-based studies demonstrate macrophages are the major target cell and identify CD206, the mannose receptor, as the tilmanocept-binding receptor. CD206 is highly expressed on the surface of tissue macrophages that are known to reside in the sentinel lymph nodes draining a primary tumor.

    Comment?

  16. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jul 22, 2015 | Business Wire

    Second Quarter 2015 Sales and Income Second quarte... )--Fitch Ratings has assigned a 'BBB' rating to the Chicago Transit Authority, Illinois $135.95 million of Series 2015 Section 5307 and $43.98 million... )--Navidea Biopharmaceuticals will report its financial results for the second quarter 2015, on Thursday, July 30, 2015 with a webcast to follow at 8:30 a.m. EDT. )--Nokia Growth Partners invests in Peloton Technology to bring truck platooning and new levels of safety and fuel efficiency to North Americ... )--Fitch Ratings withdraws 20 distressed classes in three small-balance U.S. commercial mortgage-backed securities transactions.

    Comment?

  17. Navidea Biopharmaceuticals to Announce Second Quarter 2015 Financial Results on July 30, 2015Read the original story

    Jul 22, 2015 | Information Technology

    Navidea Biopharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter 2015, on Thursday, July 30, 2015 prior to a conference call with the investment community, scheduled at 8:30 a.m. EDT. Investors and the public are invited to access the live audio webcast through the link below.

    Comment?

  18. Navidea Biopharmaceuticals Announces 2015 Annual Meeting ResultsRead the original story

    Jul 16, 2015 | Freshnews

    Navidea Biopharmaceuticals, Inc. today announced the results of voting at its 2015 Annual Meeting of Stockholders held July 16, 2015. Approximately 80 percent of outstanding shares were represented at the meeting.

    Comment?

  19. United States Breast Cancer Therapy Market Opportunity AnalysisRead the original story

    Jul 15, 2015 | Sys-Con Media

    US Breast cancer market is dominated by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin is commonly prescribed breast cancer medicine.

    Comment?

  20. Navidea Biopharmaceuticals, Inc. (NAVB) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Jul 8, 2015 | PR-inside.com

    ... .. Highlights Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. The company by ...

    Comment?